Literature DB >> 28890871

Type 2 versus type 1 myocardial infarction: a comparison of clinical characteristics and outcomes with a meta-analysis of observational studies.

Sonu Gupta1, Satyanarayana R Vaidya1, Sameer Arora1,2, Amol Bahekar3, Santhosh R Devarapally3,4.   

Abstract

BACKGROUND: Type 2 myocardial infarction (MI) is an imbalance between myocardial oxygen demand and supply, leading to myocardial ischemia. It is not due to plaque rupture, and is usually caused by a condition other than coronary artery disease (CAD). However, limited data are available comparing the prevalence of traditional coronary risk factors and mortality between type 1 and type 2 MI. We hypothesize that type 2 MI carries a higher mortality than type 1.
METHODS: We searched the databases of PubMed, EMBASE, CENTRAL, and MEDLINE for studies comparing type 1 MI with type 2 MI. The baseline variables were compared in each cohort. Summary risk ratios and 95% confidence intervals were calculated using the random effects model to compare mortality between the two groups.
RESULTS: The included studies yielded 25,872 patients of whom 2,683 (10%) had type 2 MI. Compared to the type 1 cohort, the type 2 cohort had significantly higher inpatient (15% vs. 4.7%, P<0.00001), 30-day (17.6% vs. 5.3%, P<0.00001) and 1-yr mortality (27% vs. 13%, P<0.00001), as well as higher 30-day major adverse cardiovascular events (20% vs. 9%, P<0.0001). Operative stress (20%) was the most common trigger of type 2 MI, followed by sepsis (19%), arrhythmia (18.63%), heart failure (15%), and anemia (12%).
CONCLUSIONS: Type 2 MI is a common entity and is more common in females, older age groups, and in patients with multiple comorbidities: it also tends to result in higher mortality.

Entities:  

Keywords:  Type-1 MI; type-2 MI; universal definition of MI

Year:  2017        PMID: 28890871      PMCID: PMC5582063          DOI: 10.21037/cdt.2017.03.21

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  32 in total

1.  World Health Organization definition of myocardial infarction: 2008-09 revision.

Authors:  Shanthi Mendis; Kristian Thygesen; Kari Kuulasmaa; Simona Giampaoli; Markku Mähönen; Kathleen Ngu Blackett; Liu Lisheng
Journal:  Int J Epidemiol       Date:  2010-10-05       Impact factor: 7.196

2.  Universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Harvey D White
Journal:  Eur Heart J       Date:  2007-10       Impact factor: 29.983

3.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

4.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White
Journal:  Glob Heart       Date:  2012-09-26

5.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Kristian Thygesen; Joseph S Alpert; Harvey D White; Allan S Jaffe; Hugo A Katus; Fred S Apple; Bertil Lindahl; David A Morrow; Bernard R Chaitman; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Jeroen J Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasche; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; Jose-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis; Jeroen J Bax; Helmut Baumgartner; Claudio Ceconi; Veronica Dean; Christi Deaton; Robert Fagard; Christian Funck-Brentano; David Hasdai; Arno Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Theresa McDonagh; Cyril Moulin; Bogdan A Popescu; Zeljko Reiner; Udo Sechtem; Per Anton Sirnes; Michal Tendera; Adam Torbicki; Alec Vahanian; Stephan Windecker; Joao Morais; Carlos Aguiar; Wael Almahmeed; David O Arnar; Fabio Barili; Kenneth D Bloch; Ann F Bolger; Hans Erik Botker; Biykem Bozkurt; Raffaele Bugiardini; Christopher Cannon; James de Lemos; Franz R Eberli; Edgardo Escobar; Mark Hlatky; Stefan James; Karl B Kern; David J Moliterno; Christian Mueller; Aleksandar N Neskovic; Burkert Mathias Pieske; Steven P Schulman; Robert F Storey; Kathryn A Taubert; Pascal Vranckx; Daniel R Wagner
Journal:  J Am Coll Cardiol       Date:  2012-09-05       Impact factor: 24.094

6.  TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS.

Authors:  Pedro de Araújo Gonçalves; Jorge Ferreira; Carlos Aguiar; Ricardo Seabra-Gomes
Journal:  Eur Heart J       Date:  2005-03-11       Impact factor: 29.983

7.  Type 2 myocardial infarction in clinical practice.

Authors:  Tomasz Baron; Kristina Hambraeus; Johan Sundström; David Erlinge; Tomas Jernberg; Bertil Lindahl
Journal:  Heart       Date:  2014-10-20       Impact factor: 5.994

8.  The universal classification is an independent predictor of long-term outcomes in acute myocardial infarction.

Authors:  Manuel A Gonzalez; Dana J Eilen; Rana A Marzouq; Christopher P Porterfield; Surovi Hazarika; Summiyah Nasir; Amit A Patel; Karyll De J Gonzalez; Michael B Burris; Mayelin Prieto-Gonzalez; John D Rose; Wayne E Cascio
Journal:  Cardiovasc Revasc Med       Date:  2010-10-20

9.  The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: a retrospective cohort study.

Authors:  Tor Melberg; Robert Burman; Kenneth Dickstein
Journal:  Int J Cardiol       Date:  2008-11-22       Impact factor: 4.164

10.  Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum.

Authors:  A Kumar; V Thota; L Dee; J Olson; E Uretz; J E Parrillo
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  29 in total

Review 1.  Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights.

Authors:  Jelena Kornej; Christin S Börschel; Emelia J Benjamin; Renate B Schnabel
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

2.  Variations on classification of main types of myocardial infarction: a systematic review and outcome meta-analysis.

Authors:  Kris G Vargas; Paul M Haller; Bernhard Jäger; Maximilian Tscharre; Ronald K Binder; Christian Mueller; Bertil Lindahl; Kurt Huber
Journal:  Clin Res Cardiol       Date:  2018-12-07       Impact factor: 5.460

3.  Higher non-cardiac mortality and lesser impact of early revascularization in patients with type 2 compared to type 1 acute myocardial infarction: results from the Tokyo CCU Network registry.

Authors:  Satoshi Higuchi; Makoto Suzuki; Yu Horiuchi; Hiroyuki Tanaka; Mike Saji; Hideaki Yoshino; Ken Nagao; Takeshi Yamamoto; Morimasa Takayama
Journal:  Heart Vessels       Date:  2019-01-25       Impact factor: 2.037

4.  Myocardial Infarction Type 2: Avoiding Pitfalls and Preventing Adverse Outcomes.

Authors:  Muhammad Umer Siddiqui; Adnan Ahmed; Muhammad Danial Siddiqui; Ahmed K Pasha
Journal:  Clin Med Res       Date:  2020-10-14

5.  Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.

Authors:  Christoph B Olivier; Hillary Mulder; William R Hiatt; W Schuyler Jones; F Gerry R Fowkes; Frank W Rockhold; Jeffrey S Berger; Iris Baumgartner; Peter Held; Brian G Katona; Lars Norgren; Juuso Blomster; Manesh R Patel; Kenneth W Mahaffey
Journal:  JAMA Cardiol       Date:  2019-01-01       Impact factor: 14.676

6.  Clinical variables for predicting type-1 and type-2 non-ST segment elevation myocardial infarction in those presenting with ischemic symptoms.

Authors:  Edward T Ha; Brandon Ng; Abeer Afshaq; Eitan Fleischman; Batool Hosain; Roohi Sharma; Theodore J Gaeta; Manish Parikh; Stephen J Peterson; Wilbert S Aronow
Journal:  Arch Med Sci Atheroscler Dis       Date:  2022-07-08

7.  Brief Report: Differences in Types of Myocardial Infarctions Among People Aging With HIV.

Authors:  Heidi M Crane; Robin M Nance; Bridget M Whitney; Susan R Heckbert; Matthew Budoff; Kevin High; Alan Landay; Matthew Feinstein; Richard D Moore; William Christopher Mathews; Katerina Christopoulos; Michael S Saag; Amanda Willig; Joseph J Eron; Mari M Kitahata; Joseph A C Delaney
Journal:  J Acquir Immune Defic Syndr       Date:  2021-02-01       Impact factor: 3.771

8.  Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial.

Authors:  Robert A Wise; Julie A Anderson; Pierre Amarenco; Nicholas J Cowans; Courtney Crim; Martin A Denvir; Camilo R Gomez; Matthew Pa Jones; Andrea Morris; Dennis Niewoehner; Julie C Yates
Journal:  Clin Trials       Date:  2020-05-22       Impact factor: 2.486

Review 9.  The Psycho-cardiac Coupling, Myocardial Remodeling, and Neuroendocrine Factor Levels: The Psychosomatics of Major Depressive Disorder.

Authors:  Javeria N Syeda; Ian H Rutkofsky; Adnan S Muhammad; Tarig H Balla Abdalla; Zahid Saghir
Journal:  Cureus       Date:  2018-04-11

10.  Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy.

Authors:  Christopher Reid; Ahmed Alturki; Andrew Yan; Derek So; Dennis Ko; Jean-Francois Tanguay; Amal Bessissow; Shamir Mehta; Shaun Goodman; Thao Huynh
Journal:  CJC Open       Date:  2020-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.